A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 414 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR ESMO 2024 Press Conference September 13, 2024 How to Keep Your Loved One With Cancer Safe From Infection... December 22, 2022 Texas Baby Is Born With Almost No Skin On His Body,... April 24, 2019 Remodeled CAR T-Cell Therapy Reduces Side Effects in First Clinical Trial February 20, 2020 Load more HOT NEWS Two Years After Cancer Diagnosis, Swimmer Rikako Ikee Has Qualified For... ΣΑΡΚΩΜΑ Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC... Texting May Help Reduce Disparities in Colorectal Cancer Screening
